A5088568524- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Pharmacological Effects of Natural Compounds
- Renal Diseases and Glomerulopathies
- Medical Imaging Techniques and Applications
- Chemotherapy-induced cardiotoxicity and mitigation
- Hippo pathway signaling and YAP/TAZ
- HER2/EGFR in Cancer Research
- Chronic Myeloid Leukemia Treatments
- Radiomics and Machine Learning in Medical Imaging
- Cancer Mechanisms and Therapy
- Muscle and Compartmental Disorders
- Biomedical Ethics and Regulation
- Complement system in diseases
- PI3K/AKT/mTOR signaling in cancer
- Cancer Treatment and Pharmacology
- Adrenal Hormones and Disorders
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Cytokine Signaling Pathways and Interactions
- Multiple Myeloma Research and Treatments
- Biosimilars and Bioanalytical Methods
- Cancer-related Molecular Pathways
Inserm
2023-2025
Université Paris Cité
2025
Assistance Publique – Hôpitaux de Paris
2025
Hôpital Saint-Louis
2023
HIPI - Immunologie humaine, physiopathologie et immunithérapie
2023
Centre Hospitalier Universitaire de Caen Normandie
2017-2021
Université de Caen Normandie
2017-2021
The safety profile of a rechallenge with BRAF inhibitors (BRAFi) or combination and MEK (MEKi) following an adverse drug reaction (ADR) remains largely unexplored. To identify the reported recurrence rate same ADR after BRAFi±MEKi targeted therapy (TT) in patients cancer to factors associated recurrence. In this observational, pharmacovigilance study, reports were sourced from VigiBase, World Health Organization database. inclusion criteria encompassed all BRAFi cases (with without MEKi)...